Back to results
UnknownPhase 2

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

NCT03144947

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

UO di Oncologia Ematologia, Azienda Ospedaliero Universitaria di Ferrara

Cona, Ferrara, Italy

+20 additional locations

View on ClinicalTrials.gov
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients — TrialFind